Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00991107 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production
A Phase 1 study of Insulin Resistance, sponsored by Harbor Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT00991107 is a Phase 1 study of Insulin Resistance that has completed, run by Harbor Therapeutics. The registered enrollment target is 5 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00991107, a Phase 1 study of Insulin Resistance, has completed, sponsored by Harbor Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of this study are to evaluate the safety and tolerance of 20 mg (10 mg BID) of HE3286 when administered orally over 28 days to obese insulin-resistant adult subjects and, to assess the activity of HE3286 on insulin sensitivity and hepatic glucose production in obese insulin-resistant adult subjects.
Conditions Studied
Interventions
- DRUG HE3286
Study Locations (1)
Louisiana
- Clinical Site - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00991107
The ClinicalTrials.gov registry entry for NCT00991107 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (98% lower). The listed sponsor is Harbor Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Insulin Resistance appearing as the primary indexed condition, and to 1 intervention - of which HE3286 is the first listed.
NCT00991107 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT00991107 about?
NCT00991107 is a clinical study titled "A Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production". The objectives of this study are to evaluate the safety and tolerance of 20 mg (10 mg BID) of HE3286 when administered orally over 28 days to obese insulin-resistant adult subjects and, to assess the activity of HE3286 on insulin sensitivity and hepatic glucose production in obese insulin-resistant ...
What is the current status of trial NCT00991107?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2009-09. Estimated completion is 2010-08.
What conditions does trial NCT00991107 study?
This clinical trial studies the following conditions: Insulin Resistance.
What interventions are being tested in trial NCT00991107?
The interventions under investigation include: HE3286 (DRUG).
Who is sponsoring clinical trial NCT00991107?
This trial is sponsored by Harbor Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00991107 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Resistance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
-
Graded Insulin Suppression Test P&F
RECRUITING · Phase 1
-
Diazoxide Suppression Test P&F Study
RECRUITING · Phase 1
-
Mitigating the Pro-inflammatory Phenotype of Obesity
RECRUITING · Phase 1
-
Human Models of Selective Insulin Resistance: Alpelisib, Part I
RECRUITING · Phase 1
-
Role of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.